NUCLEOLIN and lung adenocarcinoma: Further stratification according to nucleolin expression levels (nucleolinlow and nucleolinhigh, below and above the indicated quantiles determined by maximally selected ranked statistics [21]) estimated a median OS over a year longer for nucleolinlow patients relative to nucleolinhigh patients (54.3 months [95% CI: 49.1–110.5 months] and 39.9 months [95% CI: 31.3–50.2 months], respectively, p < 0.001), in the whole lung adenocarcinoma cohort (Figure 1A,B and Table S1).